Back to top

Image: Bigstock

Here's What Key Metrics Tell Us About Cross Country (CCRN) Q1 Earnings

Read MoreHide Full Article

For the quarter ended March 2026, Cross Country Healthcare (CCRN - Free Report) reported revenue of $241.06 million, down 17.8% over the same period last year. EPS came in at -$0.03, compared to $0.06 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $235.55 million, representing a surprise of +2.34%. The company delivered an EPS surprise of +36.84%, with the consensus EPS estimate being -$0.05.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Cross Country performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Nurse and allied staffing statistical data - FTEsn: 6,363 compared to the 6,411 average estimate based on two analysts.
  • Physician staffing statistical data - Revenue per day filled: $2,240.00 compared to the $2,046.50 average estimate based on two analysts.
  • Physician staffing statistical data - Days filled in HRS: 17,688 compared to the 15,611 average estimate based on two analysts.
  • Revenue- Physician staffing: $39.61 million versus $43.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -22.5% change.
  • Revenue- Nurse and allied staffing: $201.44 million compared to the $191.95 million average estimate based on three analysts. The reported number represents a change of -16.9% year over year.

View all Key Company Metrics for Cross Country here>>>

Shares of Cross Country have returned +5.6% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' 7 Best Strong Buy Stocks (New Research Report)

Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.

Click Here, It's Really Free

Published in